Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Innovent will supply sintilimab for the collaborated clinical trial
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Subscribe To Our Newsletter & Stay Updated
